Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)
The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP1) in a human airway epithelial cell line (Calu-1) and to further assess whether budesonide, a potent antiasthma corticosteroid, alters the expression and activity of MRP1 in these...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 2002-02, Vol.437 (1), p.9-17 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 1 |
| container_start_page | 9 |
| container_title | European journal of pharmacology |
| container_volume | 437 |
| creator | Bandi, Nagesh Kompella, Uday B |
| description | The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP1) in a human airway epithelial cell line (Calu-1) and to further assess whether budesonide, a potent antiasthma corticosteroid, alters the expression and activity of MRP1 in these cells. Reverse transcriptase polymerase chain reaction (RT-PCR) and the Western blot analysis demonstrated the MRP1 mRNA and MRP1 protein in Calu-1 cells. Indomethacin, probenecid, and verapamil significantly enhanced the fluorescein accumulation and reduced the fluorescein efflux, consistent with the MRP1 activity in the Calu-1 cells. Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide. At a concentration (10 μM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively. In addition, budesonide (10 μM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide. Thus, budesonide inhibits MRP1 expression and may be useful as a chemosensitizer in tumor chemotherapy. |
| doi_str_mv | 10.1016/S0014-2999(02)01267-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71478307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299902012670</els_id><sourcerecordid>71478307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-ac2c110594dd3b825b64a15b29fec60efbcfbe6c0a0da09b963cb19204cd6fd73</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhq2Kii6Fn1DkC1V7CIwdx1mfqnYFFKkSB-BsOfYEjLzJ4kn68e_r7a7osdJIo7GeGb96GDsR8FGA0J9-AAhVSWPMGchzEFK3FRywhVi2poJWyFds8R85Ym-I_gJAY2Tzmh0JsdRK1_WC5as5II1DDMgzhtkj8fWcphjy_Lu8UKTJDR4rRzT66CYMfJPHCePABcf7TUEojgMvsysV85174LiJ0x9M0SXuMSWe4oD8bOXSXInzt-ywd4nw3b4fs19fPv9cXVc3379-W13eVF6peqqcl16IkliFUHdL2XRaOdF00vToNWDf-b5D7cFBcGA6o2vfCSNB-aD70NbH7HR3t-T9NyNNdh1pG8cNOM5kW6HaZQ1bsNmBPo9EGXu7yXHt8oMVYLey7ZNsuzVpQdon2RbK3vv9B3O3xvC8tbdbgA97wJF3qc_FZKRnrlZGN40p3MWOw6LjNmK25CMW6yFm9JMNY3whyiPFv516</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71478307</pqid></control><display><type>article</type><title>Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bandi, Nagesh ; Kompella, Uday B</creator><creatorcontrib>Bandi, Nagesh ; Kompella, Uday B</creatorcontrib><description>The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP1) in a human airway epithelial cell line (Calu-1) and to further assess whether budesonide, a potent antiasthma corticosteroid, alters the expression and activity of MRP1 in these cells. Reverse transcriptase polymerase chain reaction (RT-PCR) and the Western blot analysis demonstrated the MRP1 mRNA and MRP1 protein in Calu-1 cells. Indomethacin, probenecid, and verapamil significantly enhanced the fluorescein accumulation and reduced the fluorescein efflux, consistent with the MRP1 activity in the Calu-1 cells. Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide. At a concentration (10 μM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively. In addition, budesonide (10 μM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide. Thus, budesonide inhibits MRP1 expression and may be useful as a chemosensitizer in tumor chemotherapy.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(02)01267-0</identifier><identifier>PMID: 11864633</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Blotting, Western ; Bones, joints and connective tissue. Antiinflammatory agents ; Bronchodilator Agents - pharmacology ; Budesonide ; Budesonide - pharmacology ; Calu-1 cell ; Cell Line ; Cell Survival - drug effects ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Dose-Response Relationship, Drug ; Epithelial Cells - drug effects ; Epithelial Cells - metabolism ; Gene Expression Regulation - drug effects ; Humans ; Indomethacin - pharmacology ; Lung - cytology ; Lung - drug effects ; Lung - metabolism ; Medical sciences ; MRP (Multidrug resistance-associated protein) ; Multidrug Resistance-Associated Proteins - drug effects ; Multidrug Resistance-Associated Proteins - genetics ; Multidrug Resistance-Associated Proteins - metabolism ; Pharmacology. Drug treatments ; Probenecid - pharmacology ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - drug effects ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Time Factors ; Verapamil - pharmacology ; Vincristine - pharmacology</subject><ispartof>European journal of pharmacology, 2002-02, Vol.437 (1), p.9-17</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-ac2c110594dd3b825b64a15b29fec60efbcfbe6c0a0da09b963cb19204cd6fd73</citedby><cites>FETCH-LOGICAL-c443t-ac2c110594dd3b825b64a15b29fec60efbcfbe6c0a0da09b963cb19204cd6fd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(02)01267-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13496559$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11864633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bandi, Nagesh</creatorcontrib><creatorcontrib>Kompella, Uday B</creatorcontrib><title>Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP1) in a human airway epithelial cell line (Calu-1) and to further assess whether budesonide, a potent antiasthma corticosteroid, alters the expression and activity of MRP1 in these cells. Reverse transcriptase polymerase chain reaction (RT-PCR) and the Western blot analysis demonstrated the MRP1 mRNA and MRP1 protein in Calu-1 cells. Indomethacin, probenecid, and verapamil significantly enhanced the fluorescein accumulation and reduced the fluorescein efflux, consistent with the MRP1 activity in the Calu-1 cells. Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide. At a concentration (10 μM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively. In addition, budesonide (10 μM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide. Thus, budesonide inhibits MRP1 expression and may be useful as a chemosensitizer in tumor chemotherapy.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Bronchodilator Agents - pharmacology</subject><subject>Budesonide</subject><subject>Budesonide - pharmacology</subject><subject>Calu-1 cell</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Dose-Response Relationship, Drug</subject><subject>Epithelial Cells - drug effects</subject><subject>Epithelial Cells - metabolism</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Humans</subject><subject>Indomethacin - pharmacology</subject><subject>Lung - cytology</subject><subject>Lung - drug effects</subject><subject>Lung - metabolism</subject><subject>Medical sciences</subject><subject>MRP (Multidrug resistance-associated protein)</subject><subject>Multidrug Resistance-Associated Proteins - drug effects</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Probenecid - pharmacology</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - drug effects</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Time Factors</subject><subject>Verapamil - pharmacology</subject><subject>Vincristine - pharmacology</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhq2Kii6Fn1DkC1V7CIwdx1mfqnYFFKkSB-BsOfYEjLzJ4kn68e_r7a7osdJIo7GeGb96GDsR8FGA0J9-AAhVSWPMGchzEFK3FRywhVi2poJWyFds8R85Ym-I_gJAY2Tzmh0JsdRK1_WC5as5II1DDMgzhtkj8fWcphjy_Lu8UKTJDR4rRzT66CYMfJPHCePABcf7TUEojgMvsysV85174LiJ0x9M0SXuMSWe4oD8bOXSXInzt-ywd4nw3b4fs19fPv9cXVc3379-W13eVF6peqqcl16IkliFUHdL2XRaOdF00vToNWDf-b5D7cFBcGA6o2vfCSNB-aD70NbH7HR3t-T9NyNNdh1pG8cNOM5kW6HaZQ1bsNmBPo9EGXu7yXHt8oMVYLey7ZNsuzVpQdon2RbK3vv9B3O3xvC8tbdbgA97wJF3qc_FZKRnrlZGN40p3MWOw6LjNmK25CMW6yFm9JMNY3whyiPFv516</recordid><startdate>20020215</startdate><enddate>20020215</enddate><creator>Bandi, Nagesh</creator><creator>Kompella, Uday B</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020215</creationdate><title>Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)</title><author>Bandi, Nagesh ; Kompella, Uday B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-ac2c110594dd3b825b64a15b29fec60efbcfbe6c0a0da09b963cb19204cd6fd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Bronchodilator Agents - pharmacology</topic><topic>Budesonide</topic><topic>Budesonide - pharmacology</topic><topic>Calu-1 cell</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Dose-Response Relationship, Drug</topic><topic>Epithelial Cells - drug effects</topic><topic>Epithelial Cells - metabolism</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Humans</topic><topic>Indomethacin - pharmacology</topic><topic>Lung - cytology</topic><topic>Lung - drug effects</topic><topic>Lung - metabolism</topic><topic>Medical sciences</topic><topic>MRP (Multidrug resistance-associated protein)</topic><topic>Multidrug Resistance-Associated Proteins - drug effects</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Probenecid - pharmacology</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - drug effects</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Time Factors</topic><topic>Verapamil - pharmacology</topic><topic>Vincristine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bandi, Nagesh</creatorcontrib><creatorcontrib>Kompella, Uday B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bandi, Nagesh</au><au>Kompella, Uday B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2002-02-15</date><risdate>2002</risdate><volume>437</volume><issue>1</issue><spage>9</spage><epage>17</epage><pages>9-17</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP1) in a human airway epithelial cell line (Calu-1) and to further assess whether budesonide, a potent antiasthma corticosteroid, alters the expression and activity of MRP1 in these cells. Reverse transcriptase polymerase chain reaction (RT-PCR) and the Western blot analysis demonstrated the MRP1 mRNA and MRP1 protein in Calu-1 cells. Indomethacin, probenecid, and verapamil significantly enhanced the fluorescein accumulation and reduced the fluorescein efflux, consistent with the MRP1 activity in the Calu-1 cells. Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide. At a concentration (10 μM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively. In addition, budesonide (10 μM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide. Thus, budesonide inhibits MRP1 expression and may be useful as a chemosensitizer in tumor chemotherapy.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11864633</pmid><doi>10.1016/S0014-2999(02)01267-0</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 2002-02, Vol.437 (1), p.9-17 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71478307 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antineoplastic agents Biological and medical sciences Blotting, Western Bones, joints and connective tissue. Antiinflammatory agents Bronchodilator Agents - pharmacology Budesonide Budesonide - pharmacology Calu-1 cell Cell Line Cell Survival - drug effects Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Dose-Response Relationship, Drug Epithelial Cells - drug effects Epithelial Cells - metabolism Gene Expression Regulation - drug effects Humans Indomethacin - pharmacology Lung - cytology Lung - drug effects Lung - metabolism Medical sciences MRP (Multidrug resistance-associated protein) Multidrug Resistance-Associated Proteins - drug effects Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - metabolism Pharmacology. Drug treatments Probenecid - pharmacology Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - drug effects RNA, Messenger - genetics RNA, Messenger - metabolism Time Factors Verapamil - pharmacology Vincristine - pharmacology |
| title | Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A03%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Budesonide%20reduces%20multidrug%20resistance-associated%20protein%201%20expression%20in%20an%20airway%20epithelial%20cell%20line%20(Calu-1)&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Bandi,%20Nagesh&rft.date=2002-02-15&rft.volume=437&rft.issue=1&rft.spage=9&rft.epage=17&rft.pages=9-17&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(02)01267-0&rft_dat=%3Cproquest_cross%3E71478307%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71478307&rft_id=info:pmid/11864633&rft_els_id=S0014299902012670&rfr_iscdi=true |